Keyphrases
Randomized Evaluation
50%
Pure Economic Loss
50%
COVID-19 Treatment
50%
Breach of Contract
50%
Updated Meta-analysis
50%
Platform Trials
50%
Baricitinib
50%
COVID-19
50%
Virtual Property
50%
Janus Kinase Inhibitors
25%
Usual Care
25%
Bono
10%
Meta-analysis
10%
Mortality Rate
10%
Uniform Commercial Code
8%
Pure Economics
6%
Group Care
5%
Randomized Evidence
5%
Age-adjusted Rate
5%
Possible Treatments
5%
28-day Mortality
5%
Janus Kinase
5%
Thrombosis
5%
Once-daily
5%
Corticosteroids
5%
Standard of Care
5%
Care Groups
5%
Rate Ratio
5%
Tocilizumab
5%
Risk of Death
5%
Randomized Controlled Trial
5%
Safety Outcomes
5%
Health Research
5%
Non-COVID-19
5%
Intention-to-treat
5%
Medical Research Council
5%
National Institutes of Health
5%
Social Sciences
Contract Law
100%
Courts
66%
Economic Approach
50%
Tort Law
50%
Lawyer
50%
Civil Code
8%
Subjectivity
8%
Nursing and Health Professions
Baricitinib
50%
Meta Analysis
50%
Janus Kinase Inhibitor
25%
Rate Ratio
15%
Mortality Rate
10%
Care Group
5%
Janus Kinase
5%
Tocilizumab
5%
Health Care Quality
5%
Infection
5%
National Health Organization
5%
Randomization
5%
Intention to Treat Analysis
5%
Thrombosis
5%
